JP2018508212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508212A5 JP2018508212A5 JP2017545631A JP2017545631A JP2018508212A5 JP 2018508212 A5 JP2018508212 A5 JP 2018508212A5 JP 2017545631 A JP2017545631 A JP 2017545631A JP 2017545631 A JP2017545631 A JP 2017545631A JP 2018508212 A5 JP2018508212 A5 JP 2018508212A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant listeria
- item
- listeria
- cancer
- signal sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186781 Listeria Species 0.000 claims description 127
- 238000000034 method Methods 0.000 claims description 73
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 44
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 108700026244 Open Reading Frames Proteins 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 230000001580 bacterial effect Effects 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 230000028327 secretion Effects 0.000 claims description 23
- 230000008826 genomic mutation Effects 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 18
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 230000002503 metabolic effect Effects 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 18
- 102000044159 Ubiquitin Human genes 0.000 claims description 16
- 108090000848 Ubiquitin Proteins 0.000 claims description 16
- 101150082952 ACTA1 gene Proteins 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 101710164436 Listeriolysin O Proteins 0.000 claims description 12
- 102000004357 Transferases Human genes 0.000 claims description 12
- 108090000992 Transferases Proteins 0.000 claims description 12
- 101150023527 actA gene Proteins 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 230000002238 attenuated effect Effects 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 108010041525 Alanine racemase Proteins 0.000 claims description 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000008574 D-amino acids Chemical class 0.000 claims description 6
- 241000186779 Listeria monocytogenes Species 0.000 claims description 6
- 108090001066 Racemases and epimerases Proteins 0.000 claims description 6
- 102000004879 Racemases and epimerases Human genes 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 5
- 101150030499 lnt gene Proteins 0.000 claims description 5
- 101150093386 prfA gene Proteins 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 206010070308 Refractory cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 230000001934 delay Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 206010061818 Disease progression Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000005740 tumor formation Effects 0.000 claims 1
- 101150046348 inlB gene Proteins 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021123032A JP7346501B2 (ja) | 2015-03-03 | 2021-07-28 | ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127614P | 2015-03-03 | 2015-03-03 | |
| US62/127,614 | 2015-03-03 | ||
| PCT/US2016/020571 WO2016141121A1 (en) | 2015-03-03 | 2016-03-03 | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021123032A Division JP7346501B2 (ja) | 2015-03-03 | 2021-07-28 | ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508212A JP2018508212A (ja) | 2018-03-29 |
| JP2018508212A5 true JP2018508212A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
| JP6921750B2 JP6921750B2 (ja) | 2021-08-18 |
Family
ID=56848625
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545631A Expired - Fee Related JP6921750B2 (ja) | 2015-03-03 | 2016-03-03 | ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法 |
| JP2021123032A Active JP7346501B2 (ja) | 2015-03-03 | 2021-07-28 | ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021123032A Active JP7346501B2 (ja) | 2015-03-03 | 2021-07-28 | ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10900044B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3265553A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6921750B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170120119A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107406822A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016226247B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2978082A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1248758A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL290248B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA41644A (cg-RX-API-DMAC7.html) |
| MX (1) | MX389573B (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201908086SA (cg-RX-API-DMAC7.html) |
| TW (2) | TWI728968B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016141121A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| AU2012229218B2 (en) | 2011-03-11 | 2017-03-02 | Advaxis, Inc. | Listeria-based adjuvants |
| HK1205944A1 (en) | 2012-03-12 | 2015-12-31 | 阿德瓦希斯公司 | Suppressor cell function inhibition following listeria vaccine treatment |
| JP2017511796A (ja) | 2014-02-18 | 2017-04-27 | アドバクシス， インコーポレイテッド | 多標的免疫療法を目的とするバイオマーカー |
| SG10202011841WA (en) | 2014-04-24 | 2021-01-28 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| EP3389630B1 (en) | 2015-12-16 | 2023-11-08 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| CN109641945A (zh) * | 2016-07-05 | 2019-04-16 | 阿德瓦希斯公司 | 包含维尔姆斯瘤蛋白抗原的基于李斯特菌的免疫原性组合物及其使用方法 |
| US11897927B2 (en) * | 2016-11-30 | 2024-02-13 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| WO2018102585A1 (en) * | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations |
| WO2019006401A2 (en) * | 2017-06-30 | 2019-01-03 | Advaxis, Inc. | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF |
| AU2018336988B2 (en) | 2017-09-19 | 2023-06-22 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or Listeria strains |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| MX2020004829A (es) * | 2017-11-08 | 2020-11-11 | Advaxis Inc | Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos. |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| WO2020210552A1 (en) | 2019-04-11 | 2020-10-15 | California Institute Of Technology | Methods and compositions for in vivo gene editing based cell-type-specific cellular engineering |
| CN111979162B (zh) * | 2019-05-22 | 2024-02-13 | 上海市公共卫生临床中心 | 重组卡介苗菌株、其制备方法和用途 |
| WO2020239947A1 (en) * | 2019-05-29 | 2020-12-03 | Centre National De La Recherche Scientifique | Prognosis method of leukemia |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US7820180B2 (en) | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
| US7794729B2 (en) | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
| US8956621B2 (en) | 1994-11-08 | 2015-02-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
| US7662396B2 (en) | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
| US20070264279A1 (en) | 1994-11-08 | 2007-11-15 | Claudia Gravekamp | Compositions and methods comprising a MAGE-b antigen |
| WO1998012332A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US20010043915A1 (en) | 1999-12-09 | 2001-11-22 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| AU2001255196A1 (en) | 2000-03-29 | 2001-10-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| US7700344B2 (en) | 2001-03-26 | 2010-04-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
| AUPR446801A0 (en) * | 2001-04-18 | 2001-05-17 | University Of Queensland, The | Novel compositions and uses therefor |
| WO2004062597A2 (en) | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| DK1789559T3 (en) | 2004-08-13 | 2015-08-24 | Univ Pennsylvania | Methods to construct vaccines with no antibiotic resistance |
| US7855064B2 (en) | 2004-08-13 | 2010-12-21 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free vaccines and methods for constructing and using same |
| US7858097B2 (en) | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
| US9034650B2 (en) * | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| US7935804B2 (en) * | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| US8268326B2 (en) | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
| US8241636B2 (en) | 2006-08-15 | 2012-08-14 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
| WO2008130551A2 (en) | 2007-04-16 | 2008-10-30 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free listeria strains and methods for constructing and using same |
| US20150366955A9 (en) | 2009-11-11 | 2015-12-24 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US20140234370A1 (en) | 2009-11-11 | 2014-08-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
| US20120135033A1 (en) | 2008-05-19 | 2012-05-31 | Anu Wallecha | Multiple delivery system for heterologous antigens |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| US9650639B2 (en) * | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| ES2741730T3 (es) * | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
| ES2637068T3 (es) | 2009-03-04 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Composiciones que comprenden factores angiogénicos y métodos de uso de las mismas |
| US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| US20110223187A1 (en) | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| US20110305724A1 (en) | 2010-04-19 | 2011-12-15 | Yvonne Paterson | Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof |
| US9226958B2 (en) | 2010-10-01 | 2016-01-05 | University Of Georgia Research Foundation, Inc. | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| AU2012229218B2 (en) | 2011-03-11 | 2017-03-02 | Advaxis, Inc. | Listeria-based adjuvants |
| HK1205944A1 (en) | 2012-03-12 | 2015-12-31 | 阿德瓦希斯公司 | Suppressor cell function inhibition following listeria vaccine treatment |
| EA201590397A8 (ru) | 2012-12-27 | 2016-08-31 | Адуро Биотек, Инк. | Способствующие экспрессии антигенных последовательностей у listeria партнеры для гибридизации, представляющие собой сигнальные пептиды, и способы их получения и применения |
| CN103550789B (zh) * | 2013-11-25 | 2015-04-22 | 苏州大学 | 以减毒沙门氏菌为载体的口服肿瘤疫苗的制备及其应用 |
| JP2017511796A (ja) | 2014-02-18 | 2017-04-27 | アドバクシス， インコーポレイテッド | 多標的免疫療法を目的とするバイオマーカー |
| KR20240038103A (ko) | 2014-02-25 | 2024-03-22 | 어드박시스, 인크. | Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법 |
| MA39717A (fr) | 2014-03-05 | 2017-01-11 | Advaxis Inc | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs |
| SG10202011841WA (en) | 2014-04-24 | 2021-01-28 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
| CA2947677A1 (en) | 2014-05-02 | 2015-11-05 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers |
| MX2017000838A (es) | 2014-07-18 | 2017-09-01 | Advaxis Inc | Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas. |
| EP3193921A4 (en) | 2014-07-18 | 2018-04-25 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| WO2016011320A1 (en) | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Bivalent listeria-based delivery system of heterologous antigens |
| WO2016011362A1 (en) | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
| EP3207142A4 (en) | 2014-10-14 | 2018-07-04 | The Trustees Of The University Of Pennsylvania | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| MA41217A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
| US20160220652A1 (en) | 2015-02-03 | 2016-08-04 | Advaxis, Inc. | Methods of using recombinant listeria vaccine strains in disease immunotherapy |
| WO2016126876A2 (en) | 2015-02-03 | 2016-08-11 | Advaxis, Inc. | Listeria-based adjuvants |
| WO2016126878A2 (en) | 2015-02-03 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Listeria-based immunomodulation |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| WO2016154412A2 (en) | 2015-03-26 | 2016-09-29 | The Trustees Of The University Of Pennsylvania | Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer |
| US20180104284A1 (en) | 2015-05-13 | 2018-04-19 | Advaxis, Inc. | Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof |
| KR20180026670A (ko) * | 2015-05-26 | 2018-03-13 | 어드박시스, 인크. | 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도 |
| KR20180027501A (ko) | 2015-06-24 | 2018-03-14 | 어드박시스, 인크. | 맞춤형 전달 벡터-기반 면역 요법을 위한 제조 장치 및 공정 |
| WO2017048850A1 (en) * | 2015-09-15 | 2017-03-23 | Advaxis, Inc. | Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment |
| MA42841A (fr) | 2015-09-15 | 2018-07-25 | Advaxis Inc | Procédé de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria de recombinaison |
| JP2018527382A (ja) | 2015-09-17 | 2018-09-20 | アドバクシス， インコーポレイテッド | 組み換え型リステリアワクチン株および癌免疫療法におけるその使用方法 |
| MX2018004598A (es) | 2015-10-14 | 2018-11-29 | Advaxis Inc | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. |
| WO2017085691A1 (en) | 2015-11-20 | 2017-05-26 | Advaxis, Inc. | Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain |
| US20180360940A1 (en) | 2015-12-16 | 2018-12-20 | Advaxis, Inc. | Listeria-based immunotherapy and methods of use thereof |
| MX2018009225A (es) | 2016-01-27 | 2019-08-21 | Advaxis Inc | Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. |
| CN109641945A (zh) | 2016-07-05 | 2019-04-16 | 阿德瓦希斯公司 | 包含维尔姆斯瘤蛋白抗原的基于李斯特菌的免疫原性组合物及其使用方法 |
| MA46721A (fr) | 2016-11-07 | 2019-09-11 | Advaxis Inc | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 |
| US11897927B2 (en) | 2016-11-30 | 2024-02-13 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| WO2018102585A1 (en) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations |
| WO2018129306A1 (en) | 2017-01-05 | 2018-07-12 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| WO2018170313A1 (en) | 2017-03-16 | 2018-09-20 | Advaxis, Inc. | Methods and compositions for increasing efficacy of vaccines |
| WO2019006401A2 (en) | 2017-06-30 | 2019-01-03 | Advaxis, Inc. | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF |
| AU2018336988B2 (en) | 2017-09-19 | 2023-06-22 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or Listeria strains |
| MX2020004829A (es) | 2017-11-08 | 2020-11-11 | Advaxis Inc | Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos. |
| WO2019157098A1 (en) | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| CN112074737A (zh) | 2018-03-09 | 2020-12-11 | 阿德瓦希斯公司 | 用于评估李斯特菌菌株的减毒和感染性的组合物和方法 |
| EP3785029A1 (en) | 2018-04-27 | 2021-03-03 | Advaxis, Inc. | Compositions and methods for evaluating potency of listeria-based immunotherapeutics |
-
2016
- 2016-03-02 MA MA041644A patent/MA41644A/fr unknown
- 2016-03-03 MX MX2017011246A patent/MX389573B/es unknown
- 2016-03-03 TW TW105106585A patent/TWI728968B/zh not_active IP Right Cessation
- 2016-03-03 AU AU2016226247A patent/AU2016226247B2/en not_active Ceased
- 2016-03-03 HK HK18108281.1A patent/HK1248758A1/zh unknown
- 2016-03-03 KR KR1020177024227A patent/KR20170120119A/ko active Pending
- 2016-03-03 EP EP16759454.8A patent/EP3265553A4/en not_active Withdrawn
- 2016-03-03 SG SG10201908086S patent/SG10201908086SA/en unknown
- 2016-03-03 TW TW110116020A patent/TWI808415B/zh not_active IP Right Cessation
- 2016-03-03 SG SG11201706969YA patent/SG11201706969YA/en unknown
- 2016-03-03 IL IL290248A patent/IL290248B2/en unknown
- 2016-03-03 JP JP2017545631A patent/JP6921750B2/ja not_active Expired - Fee Related
- 2016-03-03 US US15/553,507 patent/US10900044B2/en not_active Expired - Fee Related
- 2016-03-03 WO PCT/US2016/020571 patent/WO2016141121A1/en not_active Ceased
- 2016-03-03 CA CA2978082A patent/CA2978082A1/en active Pending
- 2016-03-03 CN CN201680013085.4A patent/CN107406822A/zh active Pending
-
2017
- 2017-08-28 IL IL254178A patent/IL254178B/en unknown
-
2020
- 2020-12-18 US US17/127,530 patent/US11702664B2/en active Active
-
2021
- 2021-07-28 JP JP2021123032A patent/JP7346501B2/ja active Active
-
2022
- 2022-02-01 AU AU2022200643A patent/AU2022200643B2/en not_active Ceased
-
2023
- 2023-05-12 US US18/316,539 patent/US20230357781A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508212A5 (cg-RX-API-DMAC7.html) | ||
| JP3995712B2 (ja) | 生の組換え細菌ワクチンベクターを用いる癌の特異的免疫療法 | |
| JP7197481B2 (ja) | 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法 | |
| Tondini et al. | A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control | |
| JP2013526837A5 (cg-RX-API-DMAC7.html) | ||
| JP2017195888A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507943A5 (cg-RX-API-DMAC7.html) | ||
| JP6406647B2 (ja) | 細胞性免疫誘導ワクチン | |
| JP2021502083A5 (cg-RX-API-DMAC7.html) | ||
| JP2016156828A5 (cg-RX-API-DMAC7.html) | ||
| PL1622648T3 (pl) | Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania | |
| JP2019503186A (ja) | 個別化された送達ベクターベースの免疫療法およびその使用 | |
| Fioretti et al. | Recent advances in design of immunogenic and effective naked DNA vaccines against cancer | |
| IL309716A (en) | B*44-restricted peptides for use in immunotherapy for the treatment of cancer and derived methods | |
| WO2017147160A1 (en) | A universal cancer vaccine | |
| JP2008543315A (ja) | 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物 | |
| US12018252B2 (en) | Methods and compositions for identifying neoantigens for use in treating cancer | |
| IL298653A (en) | New peptides and a combination of peptides for use in immunotherapy against several types of cancer | |
| JPWO2020097393A5 (cg-RX-API-DMAC7.html) | ||
| CA2532460A1 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| JPWO2019226939A5 (cg-RX-API-DMAC7.html) | ||
| CN110205335A (zh) | 以序列优化的分泌形式的FAPα为基础的肿瘤DNA疫苗的应用 | |
| JPWO2021216776A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | mRNA vaccines: current applications and future directions | |
| Liu et al. | Anti-tumor angiogenesis effect of genetic fusion vaccine encoding murine beta-defensin 2 and tumor endothelial marker-8 in a CT-26 murine colorectal carcinoma model |